Why the study?
TEER is an alternative for severe degenerative MR, but real-life data comparing its outcomes to surgery in older patients were needed.
Does transcatheter edge-to-edge repair (TEER) reduce a composite of all-cause death, hospitalization for heart failure or mitral valve intervention in older patients with severe symptomatic degenerative mitral regurgitation compared to surgery?
Does transcatheter edge-to-edge repair (TEER) reduce a composite of all-cause death, hospitalization for heart failure or mitral valve intervention in older patients with severe symptomatic degenerative mitral regurgitation compared to surgery?
In older patients with severe degenerative mitral regurgitation, TEER had higher unadjusted 1-year adverse event rates than surgery, but this difference was not significant after adjusting for clinical characteristics and residual MR.
Answers are grounded in this paper and cite their sources.
No adjusted difference between TEER and surgery warrants caution; leaves open need for randomized confirmation in degenerative MR.
OBJECTIVES: Transcatheter edge-to-edge repair (TEER) is an alternative for patients with severe degenerative mitral regurgitation (MR). The objective of this study was to compare the outcomes of surgery and TEER in older patients with degenerative MR patients using real life data. METHODS: Consecutives older patients (≥ 65 years-old), with severe symptomatic, degenerative MR requiring surgery or TEER between 2013 and 2023 were included. Exclusion criteria were secondary MR, and active endocarditis. Primary outcome was a composite of all-cause death, hospitalization for heart failure or mitral valve intervention within one year. RESULTS: A total of 295 patients were included (203 underwent surgery and 92 underwent TEER). At 1 year, 26 (9%) patients had died, required reintervention or rehospitalization for heart failure: 8 patients in the surgery group (4%) and 18(20%) in the TEER group(p < 0.01). Factors independently associated with the combined outcome were residual MR > 2 (aHR 4.31 (95% CI: 1.51-12.25)), history of cardiac surgery (aHR 6.24 (95%CI: 2.16-18.05)), BMI (aHR 0.88 (95% CI: 0.77-0.98)), TR > 2 at baseline (aHR: 2.47 (95% CI: 1.03-5.91)). After adjustement on confounding factors, intervention type was not associated with the primary composite outcome (aHR: 3.41 (95% CI: 0.63-18.27)), p = 0.15). CONCLUSION: Patients with severe primary MR treated with TEER experienced a higher rate of adverse events within one year compared to surgically managed patients. However, these differences were mainly associated to clinical characteristics and were no longer significant after adjustment on residual MR > 2.
No takes yet. Share an insight, caveat, or question.
Suc et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: